Help appealing denials for this first self-administered nasal spray for PSVT episodes.

Appeal Your Cardamyst Denial

Get access to the first at-home treatment for acute PSVT episodes.

Understanding Your Cardamyst (etripamil) nasal spray Denial

Cardamyst (etripamil) is the first and only self-administered nasal spray approved for converting acute paroxysmal supraventricular tachycardia (PSVT) episodes to normal heart rhythm. This means you can treat episodes at home instead of going to the emergency room. Insurance denials often cite preference for ER treatment or questions about PSVT diagnosis.

Common Reasons for Denial

! Prior authorization required
! PSVT diagnosis not adequately documented
! Preference for emergency department treatment
! Not medically necessary
! New drug with limited coverage policies
! Step therapy through vagal maneuvers first

How We Help

We help you document your PSVT diagnosis, frequency of episodes, impact on quality of life, and prior emergency room visits to demonstrate why at-home treatment is medically necessary and cost-effective.

Start your Cardamyst appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Etripamil nasal spray provides rapid conversion of PSVT episodes, with most conversions occurring within 30 minutes of administration.

✓ Self-administered PSVT treatment significantly reduces emergency department utilization and associated healthcare costs.

✓ PSVT affects over 2 million Americans and causes significant anxiety, loss of work productivity, and impaired quality of life.

✓ At-home treatment options for PSVT align with patient-centered care principles and reduce burden on emergency services.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

StopAfib.org

Patient advocacy organization founded by and for afib patients.

Frequently Asked Questions

Cardamyst allows you to treat PSVT episodes at home, avoiding the time, cost, and stress of emergency room visits. For many patients, this significantly improves quality of life and reduces healthcare costs.

Include your electrophysiology study or EKG documentation of PSVT, records of prior ER visits for PSVT, documentation of episode frequency, and a letter from your cardiologist or electrophysiologist.

Cardamyst is a calcium channel blocker delivered as a nasal spray that works to convert PSVT episodes back to normal sinus rhythm. It's designed to be self-administered during an episode.

Ready to Fight Your Cardamyst (etripamil) nasal spray Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including Milestone Pharmaceuticals. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.